ImmunoGen Gets FDA Priority Review for Elahere sBLA
About 67% of ImmunoGen's investor base is looking to short. The analysis of current outlook of investing in ImmunoGen suggests that many traders are alarmed regarding ImmunoGen's prospects. ImmunoGen's investing sentiment overview a quick insight into current market opportunities from investing in ImmunoGen. Many technical investors use ImmunoGen stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
ImmunoGen |
The FDA grants priority review to ImmunoGens sBLA to convert the accelerated approval for Elahere to full approval for treating platinum-resistant ovarian cancer. A decision is due on Apr 5, 2024.
Read at finance.yahoo.com
 |
ImmunoGen Fundamental Analysis
We analyze ImmunoGen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmunoGen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmunoGen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash And Equivalents
Cash And Equivalents Comparative Analysis
ImmunoGen is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
ImmunoGen Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ImmunoGen stock to make a market-neutral strategy. Peer analysis of ImmunoGen could also be used in its relative valuation, which is a method of valuing ImmunoGen by comparing valuation metrics with similar companies.
Peers
ImmunoGen Related Equities
| XFOR | X4 Pharmaceuticals | 8.11 | ||||
| TGTX | TG Therapeutics | 5.47 | ||||
| MCRB | Seres Therapeutics | 4.11 | ||||
| HOOK | Hookipa Pharma | 2.00 | ||||
| MDGL | Madrigal Pharmaceuticals | 1.65 | ||||
| AXSM | Axsome Therapeutics | 0.89 | ||||
| VKTX | Viking Therapeutics | 0.70 | ||||
| AKRO | Akero Therapeutics | 0.34 | ||||
| INZY | Inozyme Pharma | 0.83 | ||||
| TERN | Terns Pharmaceuticals | 1.86 | ||||
| PDSB | PDS Biotechnology | 2.21 | ||||
| MREO | Mereo BioPharma | 2.78 | ||||
| ELEV | Elevation Oncology | 5.45 | ||||
| HEPA | Hepion Pharmaceuticals | 7.14 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in ImmunoGen Stock
If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |